youtube_live
Q3 2026 earnings • released • EPS beat +17.95%
See resultschevron_right
DFTX:NASDAQ
Definium Therapeutics Inc
$34.40
arrow_downward
-2.80%(-0.99) 1D
Nov 10, 1:08:03 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DFTX...
Open
$34.45
High
$35.97
Low
$33.78
Mkt. cap
4.62B
Avg. vol.
1.92M
Volume
605.63K
52-wk high
$49.70
52-wk low
$14.62
EPS
-$3.43
Beta
2.23
Shares outstanding
134.37M
No. of employees
106
Open
$34.45
High
$35.97
Low
$33.78
Mkt. cap
4.62B
Avg. vol.
1.92M
Volume
605.63K
52-wk high
$49.70
52-wk low
$14.62
EPS
-$3.43
Beta
2.23
Shares outstanding
134.37M
No. of employees
106
News stories
From web sources and news partners
GuruFocus
·
1 hour ago
DFTX Maintained by RBC Capital -- Price Target Raised to $70
TradingView
·
2 hours ago
DFTX: DT120 targets an H1 2027 NDA; early DT402 findings support continued ASD development
kalkine.ca
·
3 hours ago
Is USD 1.05 Billion in Cash Enough to Carry Definium (NASDAQ:DFTX) Through an Anxiety Filing?
Yahoo Finance
·
17 hours ago
What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call
Profile
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs. Wikipedia
About Definium Therapeutics Inc
CEORobert Barrow
Employees106
Founded2010
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitedefiniumtx.com
Analyst ratings
Based on 15 analysts giving stock ratings to DFTX in the past 3 months
Strong buy
Buy
15
Hold
0
Sell
0
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for DFTX in the last 3 months.
Highest
Current $34.40
$91.00 (+164.53%)
Average
$73.64 (+114.07%)
Lowest
$55.00 (+59.88%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Tessa Romero J.P. Morgan | Buy | Maintained | - | - | 11/09/2026 |
Jay Olson Oppenheimer | Buy | Maintained | $75.00 | +118% | 11/10/2026 |
Ami Fadia Needham | Buy | Reiterated | $66.00 | +91.9% | 11/10/2026 |
Sumant Kulkarni Canaccord Genuity | Buy | Reiterated | $78.00 | +126.7% | 11/10/2026 |
David Amsellem Piper Sandler | Buy | Reiterated | $75.00 | +118% | 11/10/2026 |
Tazeen Ahmad Bank of America Securities | Buy | Reiterated | $91.00 | +164.5% | 11/09/2026 |
Brian Abrahams RBC Capital | Buy | Reiterated | $70.00 | +103.5% | 11/09/2026 |
Patrick Trucchio H.C. Wainwright | Buy | Reiterated | $70.00 | +103.5% | 11/09/2026 |
Francois Brisebois LifeSci Capital | Buy | Maintained | $78.00 | +126.7% | 09/19/2026 |
Michael Okunewitch Maxim Group | Buy | Maintained | $55.00 | +59.9% | 09/15/2026 |
Paul Matteis Stifel Nicolaus | Buy | Maintained | $67.00 | +94.8% | 09/15/2026 |
Justin Walsh JonesTrading | Buy | Reiterated | $90.00 | +161.6% | 09/15/2026 |
Christopher Chen Robert W. Baird | Buy | Maintained | $79.00 | +129.7% | 09/15/2026 |
Benjamin Burnett Wells Fargo | Buy | Maintained | $72.00 | +109.3% | 08/31/2026 |
Andrew Tsai Jefferies | Buy | Maintained | $65.00 | +89% | 08/13/2026 |
Unknown Analyst Evercore ISI | Buy | Maintained | $53.00 | +54.1% | 08/10/2026 |
Gavin Clark-Gartner Evercore ISI | Buy | Maintained | $26.00 | -24.4% | 03/02/2026 |
Rudy Li Wolfe Research | Buy | Initiated | $25.00 | -27.3% | 02/23/2026 |
Last report
Nov 9, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
-$0.46 / -$0.56
+17.95%beat
arrow_upward
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | - | - | - | - |
Cost of goods sold | - | - | - | - |
Cost of revenue | - | - | - | - |
Research and development expenses | 30.98M | 33.52M | 41.48M | 48.66M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 14.69M | 14.06M | 17.74M | 26.41M |
Operating expense | 45.67M | 47.58M | 59.22M | 75.08M |
Total operating expenses | 45.67M | 47.58M | 59.22M | 75.08M |
Operating income | -45.67M | -47.58M | -59.22M | -75.08M |
Other non operating income | -22.54M | -5.06M | -20.05M | -86.23M |
EBT including unusual items | -67.26M | -50.44M | -77.10M | -158.99M |
EBT excluding unusual items | -67.26M | -50.44M | -77.10M | -158.99M |
Income tax expense | - | - | - | - |
Effective tax rate | - | - | - | - |
Other operating expenses | - | - | - | - |
Net income | -67.26M | -50.44M | -77.10M | -158.99M |
Net profit margin | - | - | - | - |
Earnings per share | -0.78 | - | - | -1.44 |
Interest and investment income | 2.26M | 3.49M | 3.46M | 3.59M |
Interest expense | -1.27M | -1.27M | -1.24M | -1.23M |
Net interest expenses | 988.00K | 2.22M | 2.21M | 2.35M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -45.66M | -47.57M | - | - |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events